Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients

Abroad (travel likely)RecruitingPHASE2

Conditions

Duchenne Muscular Dystrophy · Duchenne · DMD · Neuromuscular Diseases · Muscular Dystrophies

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of California Los Angeles, Los Angeles, California, United States
Contact: Study coordinator (Denisse Velazquez) · Denissevelazquez@mednet.ucla.edu · 310-825-3264
Colorado Children's, Aurora, Colorado, United States
Contact: Study coordinator (Nana Welnick) · Nanastasia.Welnick@childrenscolorado.org · 720-777-8608
Lurie Children's, Chicago, Illinois, United States
Contact: Study coordinator (Alka Maheshwari) · amaheshwari@luriechildrens.org · 312-227-3813
UMass Memorial Medical Center, Worcester, Massachusetts, United States
Contact: Study coordinator (Sarah Figueira) · Sarah.figueira@umassmed.edu · 508-856-1604
Washington University, St Louis, Missouri, United States
Contact: Study coordinator (Natalie Goedeker) · NeuromusclePediatricResearch@wustl.edu · 314-362-4919
Nationwide Children's Hospital, Columbus, Ohio, United States
Contact: Study coordinator (Jeremy Thompson) · jeremy.thompson@nationwidechildrens.org · 614-355-2923
Seattle Children's, Seattle, Washington, United States
Contact: Study coordinator (Marissa Robertson) · marissa.robertson@seattlechildrens.org · 206-987-5457
Children's Hospital at Westmead, Westmead, New South Wales, Australia
Contact: Study coordinator (Natasha Edirisinghege) · Natasha.Edirisinghege@health.nsw.gov.au
Royal Children's Hospital Melbourne, Melbourne, Victoria, Australia
Contact: Study coordinator (Ian Woodcock, MD) · neurology.department@rch.org.au
Hôpital De La Citadelle (CHR), Liège, Liège, Belgium
Contact: Study coordinator (Laurie Medard) · laurie.medard@citadelle.be
UZ Gent, Ghent, Oost-Vlaanderen, Belgium
Contact: Study coordinator (Julie Vancraeynest) · julie.vancraeynest@uzgent.be · +32 9 332 83 29
Children's Hospital Eastern Ontario, Ottawa, Ontario, Canada
Contact: Study coordinator (Emilie Hill-Smith) · EHillSmith@cheo.on.ca
Klinika Neurologii Rozwojowej Uniwersyteckie, Gdansk, Pomeranian Voivodeship, Poland
Contact: Study coordinator (Angelika Kamińska) · ankaminska@uck.gda.pl · 48 58 349 23 31
Instytut Centrum Zdrowia Matki Polki, Lodz, Łódź Voivodeship, Poland
Contact: Study coordinator (Joanna Wawrzynczak) · joanna.wawrzynczak@iczmp.edu.pl · 48 42 271-16-11
Clinic of Neurology and Psychiatry for Children and Youth, Belgrade, Serbia, Serbia
Contact: Study coordinator (Ana Kosac) · kosacana@gmail.com
University Children's Clinic Tirsova, Belgrade, Serbia, Serbia
Contact: Study coordinator (Raus Misela) · michelleraus@gmail.com
Mother and Child Health Care Institute, Belgrade, Serbia, Serbia
Contact: Study coordinator (Snezana Popovic) · andjajockic@gmail.com
Hospital Universitario Donostia, Donostia / San Sebastian, Basque Country, Spain
Contact: Study coordinator (Josune Domínguez García) · JOSUNE.DOMINGUEZGARCIA@bio-gipuzkoa.eus · +34 943 00 76 39
Hospital Universitario y Politécnico La Fe, Valencia, Valencia, Spain
Contact: Study coordinator (Marta Campo Rodrigo) · marta_campo@iislafe.es · +34 630306333434654
Hospital Infantil i Hospital de la Dona, Barcelona, Spain
Contact: Study coordinator (Juan José Palmí Perales) · juan.palmi@vhir.org · +34 671 712 875
Great Ormond Street, London, UK, United Kingdom
Contact: Study coordinator (Marta Zancolli) · m.zancolli@ucl.ac.uk

Study leads

Satellos Chief Medical Officer
Study Director
Satellos Bioscience, Inc.

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)

Duchenne Muscular Dystrophy (DMD) · Muscular Dystrophy, Duchenne · Muscular Dystrophy (DMD)

Abroad (travel likely)RecruitingPHASE3

Hillsborough, United States

A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44

Duchenne Muscular Dystrophy (DMD)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Ghent, Belgium · Leuven, Belgium

PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)

Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD

Abroad (travel likely)RecruitingPHASE1, PHASE2

Little Rock, United States · St Louis, United States

Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Abroad (travel likely)RecruitingPHASE3

Leuven, Belgium · Vancouver, Canada